- Details
- Rashid Sayyid and Zach Klaassen explore a study by Brian Cortese and Ruchika Talwar regarding potential savings through generic oncology drugs purchased via Mark Cuban's Cost Plus Drug Company (MCCPDC) compared to Medicare. The study focuses on the economic impacts of high-priced generic oncology drugs, the financial toxicity experienced by patients, and how MCCPDC can help mitigate these problems...
|
- Details
- In a discussion Rashid Sayyid and Zach Klaassen, they delve into a study comparing advanced molecular imaging and conventional imaging in detecting metachronous oligometastatic castrate-sensitive prostate cancer. The study used data from phase two trials, including the STOMP and ORIOLE trials, which established the oncologic benefits of metastasis-directed therapy for patients with metachronous ol...
|
- Details
- Rashid Sayyid and Zach Klaassen present the CONTACT-03 trial examining the combination of atezolizumab plus cabozantinib compared to cabozantinib monotherapy in patients with renal cell carcinoma (RCC) who have progressed following prior immune checkpoint inhibitor treatment. Dr. Sayyid discusses the evolution of treatment for advanced or metastatic RCC, highlighting the emergence of immune checkp...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the COSMIC-313 clinical trial, examining the use of cabozantinib, nivolumab, and ipilimumab in renal cell carcinoma treatment. Published in the New England Journal of Medicine, the study focuses on patients with locally advanced or metastatic clear cell carcinoma. The trial, a phase III randomized, double-blind, placebo-controlled study, encompassed approxim...
|
- Details
- Rashid Sayyid and Zach Klaassen analyze an ad hoc analysis from the VISION study, published in the Journal of Nuclear Medicine. The study investigates the agreement between readers in the interpretation of 68Ga-PSMA-11 PET/CT scans to determine patient eligibility for 177Lu-PSMA-617 Radioligand Therapy in the treatment of prostate cancer. They elaborate on the study's methodology, including the re...
|
- Details
- Rashid Sayyid and Zach Klaassen, dissect a publication from the VISION study regarding health-related quality of life and pain outcomes with Lu-PSMA-617+ Standard of Care versus Standard of Care alone in patients with mCRPC. This study, conducted across 84 global centers, reveals that the addition of Lu-PSMA-617 to standard care significantly improved overall survival rates from 11.3 to 15.3 month...
|
- Details
- Rashid Sayyid and Zach Klaassen shed light on the TALAPRO-2 study published in The Lancet. This study evaluated the combination of talazoparib, a potent PARP inhibitor, and enzalutamide in treating men with first-line metastatic castration-resistant prostate cancer (mCRPC). They note the poor prognosis for patients with mCRPC and the need for more effective treatments, especially for those with ho...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss a publication examining metastatic prostate cancer outcomes in relation to BRCA2 and ATM mutations. Sayyid highlights that around 20-25% of metastatic prostate cancer patients have homologous recombination repair (HRR) gene mutations which are not uniform and can significantly affect treatment responses. He explains that FDA-approved PARP inhibitors (olapari...
|
- Details
- Rashid Sayyid and Zach Klaassen a paper on the development of a patient-reported outcomes (PROs) measure for radionuclide therapy for prostate cancer, published in the Journal of Nuclear Medicine. They explain the importance of PROs in evaluating the impact of these emerging oncology treatments on patients' quality of life. Highlighting a current gap in the literature, they note that existing PRO...
|
- Details
- In this discussion, Rashid Sayyid and Zach Klaassen discuss the findings of a study investigating the significance of bone biomarkers in the prognosis of men with hormone-sensitive prostate cancer. The study, a subgroup analysis from the SWOG S1216 trial, used blood-based biomarkers of bone turnover as prognostic factors for survival. It also examined the performance of Orteronel, a non-steroidal...
|
